These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 6423811)

  • 1. Effects of a new aldose reductase inhibitor on various tissues in vitro.
    Terashima H; Hama K; Yamamoto R; Tsuboshima M; Kikkawa R; Hatanaka I; Shigeta Y
    J Pharmacol Exp Ther; 1984 Apr; 229(1):226-30. PubMed ID: 6423811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of a new aldose reductase inhibitor, (E)-3-carboxymethyl-5-[(2E)-methyl-3-phenylpropenylidene]rhodanine (ONO-2235) on peripheral nerve disorders in streptozotocin-diabetic rats.
    Kikkawa R; Hatanaka I; Yasuda H; Kobayashi N; Shigeta Y; Terashima H; Morimura T; Tsuboshima M
    Diabetologia; 1983 Apr; 24(4):290-2. PubMed ID: 6407887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isoliquiritigenin: a new aldose reductase inhibitor from glycyrrhizae radix.
    Aida K; Tawata M; Shindo H; Onaya T; Sasaki H; Yamaguchi T; Chin M; Mitsuhashi H
    Planta Med; 1990 Jun; 56(3):254-8. PubMed ID: 2118267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of peripheral nerve dysfunction by an aldose reductase inhibitor in streptozotocin-diabetic rats.
    Kikkawa R; Hatanaka I; Yasuda H; Kobayashi N; Shigeta Y
    Metabolism; 1984 Mar; 33(3):212-4. PubMed ID: 6420645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of an aldose reductase inhibitor, ONO-2235, insulin and their combination on the altered responsiveness to the nerve stimulation and agonists of the isolated atria of diabetic rats.
    Hashimoto H; Satoh N; Takiguchi Y; Nakashima M
    J Pharmacol Exp Ther; 1990 May; 253(2):552-7. PubMed ID: 2159998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AL-1576, an aldose reductase inhibitor (ARI), did not prevent the decrease of norepinephrine turnover in diabetic rats.
    Yen TT; Fuller RW; Broderick CL; Hemrick-Luecke SK; Perry KW
    Res Commun Chem Pathol Pharmacol; 1988 Aug; 61(2):257-60. PubMed ID: 3141993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of a fructose-rich diet and the aldose reductase inhibitor, ONO-2235, on the development of diabetic neuropathy in streptozotocin-treated rats.
    Hotta N; Kakuta H; Fukasawa H; Kimura M; Koh N; Iida M; Terashima H; Morimura T; Sakamoto N
    Diabetologia; 1985 Mar; 28(3):176-80. PubMed ID: 3922829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetic complications in lens and nerve and their prevention by sulindac or sorbinil: two novel aldose reductase inhibitors.
    Jacobson M; Sharma YR; Cotlier E; Hollander JD
    Invest Ophthalmol Vis Sci; 1983 Oct; 24(10):1426-9. PubMed ID: 6413448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of aldose reductase inhibitor (ONO-2235) on human erythrocyte sorbitol concentrations in 75 g oral glucose tolerance tests.
    Kamon N; Mabuchi H; Takeda R; Terashima H
    Horm Metab Res; 1991 May; 23(5):226-9. PubMed ID: 1908433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of aldose reductase inhibitor on the peripheral nerve function during ischemia in diabetics.
    Kuriya N; Miyake S; Yokota A; Yamaguchi Y; Nakanishi T; Takahashi A; Ueda Y; Mori T; Akiguchi I; Toyama K
    J Med Assoc Thai; 1987 Mar; 70 Suppl 2():168-72. PubMed ID: 3110345
    [No Abstract]   [Full Text] [Related]  

  • 11. Photo-stabilization and solubilization of an aldose reductase inhibitor, (E)-3-carboxymethyl-5-[(2E)-methyl-3-phenylpropenylidene]rhodani ne (ONO-2235), by human serum albumin.
    Kurono Y; Furukawa A; Takesue Y; Li FL; Ikeda K
    Chem Pharm Bull (Tokyo); 1987 Jul; 35(7):3045-8. PubMed ID: 3119240
    [No Abstract]   [Full Text] [Related]  

  • 12. The role of cyclic adenosine 3',5'-monophosphate and polyol metabolism in diabetic neuropathy.
    Shindo H; Tawata M; Aida K; Onaya T
    J Clin Endocrinol Metab; 1992 Feb; 74(2):393-8. PubMed ID: 1370506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of aldose reductase inhibitor on retinal microangiopathy in streptozotocin-diabetic rats.
    Kojima K; Matsubara H; Harada T; Mizuno K; Suzuki M; Hotta N; Kakuta H; Sakamoto N
    Jpn J Ophthalmol; 1985; 29(1):99-109. PubMed ID: 3159927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of aldose reductase inhibitor ONO 2235 on reduced sympathetic nervous system activity and peripheral nerve disorders in STZ-induced diabetic rats.
    Yoshida T; Nishioka H; Yoshioka K; Nakano K; Kondo M; Terashima H
    Diabetes; 1987 Jan; 36(1):6-13. PubMed ID: 3025043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polyol pathway in tissues of spontaneously diabetic Chinese hamsters (Cricetulus griseus) and the effect of an aldose reductase inhibitor, ONO-2235.
    Sekiguchi M; Watanabe K; Eto M; Iwashima Y; Morikawa A; Takahashi M; Ishii K; Makino I
    Comp Biochem Physiol B; 1991; 98(4):637-40. PubMed ID: 1907900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CP-45,634: a novel aldose reductase inhibitor that inhibits polyol pathway activity in diabetic and galactosemic rats.
    Peterson MJ; Sarges R; Aldinger CE; MacDonald DP
    Metabolism; 1979 Apr; 28(4 Suppl 1):456-61. PubMed ID: 122297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory effects of Ganoderma applanatum on rat lens aldose reductase and sorbitol accumulation in streptozotocin-induced diabetic rat tissues.
    Jung SH; Lee YS; Shim SH; Lee S; Shin KH; Kim JS; Kim YS; Kang SS
    Phytother Res; 2005 Jun; 19(6):477-80. PubMed ID: 16114079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Properties of ICI 128,436, a novel aldose reductase inhibitor, and its effects on diabetic complications in the rat.
    Stribling D; Mirrlees DJ; Harrison HE; Earl DC
    Metabolism; 1985 Apr; 34(4):336-44. PubMed ID: 3920474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of prostaglandin E1 analogue TFC 612 on diabetic neuropathy in streptozocin-induced diabetic rats. Comparison with aldose reductase inhibitor ONO 2235.
    Yasuda H; Sonobe M; Yamashita M; Terada M; Hatanaka I; Huitian Z; Shigeta Y
    Diabetes; 1989 Jul; 38(7):832-8. PubMed ID: 2525492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Properties of novel aldose reductase inhibitors, M16209 and M16287, in comparison with known inhibitors, ONO-2235 and sorbinil.
    Kato K; Nakayama K; Mizota M; Miwa I; Okuda J
    Chem Pharm Bull (Tokyo); 1991 Jun; 39(6):1540-5. PubMed ID: 1934175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.